Search results
AstraZeneca earmarks $1.5B for end-to-end ADC factory in Singapore
Endpoints News· 6 days agoAstraZeneca said on Monday morning it is building a new antibody-drug conjugate facility in...
AstraZeneca aims for $80 bln in total revenue by 2030
Reuters· 5 days ago, opens new tab aims to grow revenue by about 75% to $80 billion by 2030, it said on Tuesday,...
AstraZeneca (LON:AZN) Earns “Buy” Rating from Shore Capital
ETF DAILY NEWS· 2 days agoShore Capital reissued their buy rating on shares of AstraZeneca (LON:AZN – Free Report) in a research report report published on Tuesday morning, Marketbeat Ratings reports ...
AstraZeneca sets bold revenue target as CEO aims to double sales to $80 billion by 2030
Fortune· 5 days agoThe company, which generated $45.8 billion in revenue last year, will launch 20 new medicines by the end of the decade to meet the new total revenue target, Astra said Tuesday. The revenue goal ...
AstraZeneca Targets $80B Revenue by 2030 Through Pipeline Expansion
Market Watch· 5 days agoBy Helena Smolak AstraZeneca has set out a target to grow revenue to $80 billion by 2030 as it aims to bolster its investment in technologies and platforms....
AstraZeneca aims increase its annual revenue by 75% in its post-COVID era
Quartz· 5 days agoCambridge, U.K.-based pharmacuetical giant AstraZeneca announced an ambitious sales goal for the end of this decade, just as it pulls it COVID-19 vaccines off the shelves.
AstraZeneca kicks off 'new era of growth' with aim to hit $80 billion of sales by 2030
Morningstar· 5 days agoAstraZeneca on Tuesday outlined ambitions to almost double its sales over the next six years by launching 20 new medicines by 2030. In a statement, the Anglo-Swedish pharmaceutical ...
AstraZeneca’s fasenra asthma drug shows promise for COPD treatment
BioPharma-Reporter· 5 days agoThis approval extends Fasenra's availability to over 80 countries, including the US, EU, and Japan....
AstraZeneca to build $1.5-bln cancer drug plant in Singapore
Reuters· 6 days ago, opens new tab plans to build a $1.5 billion manufacturing facility in Singapore to produce a...
AstraZeneca's new 2030 targets are bold attempt to reach for the stars, say analysts
Proactive Investors· 5 days agoAfter AstraZeneca PLC (LSE:AZN) unveiled new sales and profit targets for the end of the decade,...